Philip Anthony Sutera

Philip Sutera practices at Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD in Rochester, New York.

Philip Sutera's NPI, 1376100255, was assigned on May 25, 2019. Philip Sutera graduated from University of Pittsburgh School of Medicine in 2019. Philip Sutera holds New York license 330269.

Philip Sutera's primary practice is Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD, at 1000 South Ave, Rochester, NY 14620.

Philip Sutera's primary practice is Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD in Rochester, New York. Philip Sutera is also affiliated with Highland Hospital. The medical group on file is University of Rochester Medical Faculty Group (URMFG). Dmand AI also links Philip Sutera to 2 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Philip Sutera practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Philip Sutera's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Philip Sutera is licensed in New York.

CMS counts 21 Medicare patients who saw Philip Sutera in 2024. 75% of them have cancer, and 67% have high cholesterol. Their average risk score is 1.22, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Philip Sutera's median patient age at 71, with 40% women.

In 2024, Philip Sutera wrote 67 Medicare Part D claims for 37 patients. 85% of them were for generic drugs. CMS names the drug for 59 of them, across 4 drugs with 11 or more claims each, at $1,358 in total drug cost. In 2020, CMS named 19 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Philip Sutera for performance year 2024, reported as part of a group. Philip Sutera accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Philip Sutera as offering telehealth.

Dmand AI links 39 papers to Philip Sutera, published from 2014 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Neoplasm Metastasis. Philip Sutera has published most often in Eur Urol Oncol. Philip Sutera's most frequent co-authors are Matthew Pierre Deek, MD, Phuoc T. Tran, MD, PhD and Ana Ponce Kiess, MD, PhD.

CMS Open Payments shows 2 general payments to Philip Sutera from 1 drug or device company from 2022 to 2023. Food and beverage make up the largest share, 100% of the total. RefleXion Medical, Inc. paid the most, $379.

Philip Sutera graduated from University of Pittsburgh School of Medicine in 2019.